Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019982783> ?p ?o ?g. }
- W2019982783 endingPage "758" @default.
- W2019982783 startingPage "747" @default.
- W2019982783 abstract "Introduction: The primary sulfonamide moiety is present in many clinically used drugs, such as diuretics (furosemide, indapamide, chlorthalidone, thiazides); carbonic anhydrase (CA) inhibitors (CAIs) (including acetazolamide, dichlorophenamide, dorzolamide and brinzolamide); antiepileptics (zonisamide and sulthiame); the antipsychotic sulpiride and the cycloxygenase 2 (COX2) inhibitors celecoxib and valdecoxib. Recently, novel drugs have been launched, such as apricoxib and pazopanib, which also incorporate this group. Areas covered: The article presents the main classes of sulfonamides investigated between 2008 and 2012. Specifically, the authors review the scientific and patent literature on CAIs, COX2 inhibitors, pazopanib and its congeners, which are multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit. Expert opinion: Most patents deal with sulfonamide CAIs incorporating NO-donating moieties as antiglaucoma agents, or with compounds targeting the tumor-associated isoforms CA IX/XII. The antidandruff actions of sulphonamides, which inhibit yeast CAs, were also claimed. Apricoxib (a COX2 inhibitor) and pazopanib, a tyrosine kinase inhibitor, show significant antitumor activity and several patents deal with these drugs. There is a constant need of novel sulfonamides to act as selective antiglaucoma drugs (targeting CA II), as antitumor agents/diagnostic tools (targeting CA IX/XII), and to treat and diagnose other disease. This privileged structural motif is likely to be present in other drugs in the future." @default.
- W2019982783 created "2016-06-24" @default.
- W2019982783 creator A5012797490 @default.
- W2019982783 creator A5035013697 @default.
- W2019982783 creator A5072935995 @default.
- W2019982783 date "2012-06-15" @default.
- W2019982783 modified "2023-10-11" @default.
- W2019982783 title "Sulfonamides: a patent review (2008 – 2012)" @default.
- W2019982783 cites W1549224984 @default.
- W2019982783 cites W1570661615 @default.
- W2019982783 cites W1966193253 @default.
- W2019982783 cites W1966290213 @default.
- W2019982783 cites W1969303265 @default.
- W2019982783 cites W1971905772 @default.
- W2019982783 cites W1973469475 @default.
- W2019982783 cites W1976495896 @default.
- W2019982783 cites W1979987305 @default.
- W2019982783 cites W1988781906 @default.
- W2019982783 cites W1990331048 @default.
- W2019982783 cites W2003278910 @default.
- W2019982783 cites W2005340426 @default.
- W2019982783 cites W2007695861 @default.
- W2019982783 cites W2014677435 @default.
- W2019982783 cites W2022203610 @default.
- W2019982783 cites W2028948269 @default.
- W2019982783 cites W2029953509 @default.
- W2019982783 cites W2030082143 @default.
- W2019982783 cites W2030793740 @default.
- W2019982783 cites W2030858021 @default.
- W2019982783 cites W2034233153 @default.
- W2019982783 cites W2034434306 @default.
- W2019982783 cites W2038503864 @default.
- W2019982783 cites W2044012966 @default.
- W2019982783 cites W2044044962 @default.
- W2019982783 cites W2045122623 @default.
- W2019982783 cites W2045271160 @default.
- W2019982783 cites W2045312722 @default.
- W2019982783 cites W2047178318 @default.
- W2019982783 cites W2049308355 @default.
- W2019982783 cites W2049312911 @default.
- W2019982783 cites W2050046796 @default.
- W2019982783 cites W2050578721 @default.
- W2019982783 cites W2051349300 @default.
- W2019982783 cites W2062158179 @default.
- W2019982783 cites W2063207963 @default.
- W2019982783 cites W2066665206 @default.
- W2019982783 cites W2068210639 @default.
- W2019982783 cites W2068750741 @default.
- W2019982783 cites W2072458613 @default.
- W2019982783 cites W2081972370 @default.
- W2019982783 cites W2088895364 @default.
- W2019982783 cites W2089182854 @default.
- W2019982783 cites W2089542754 @default.
- W2019982783 cites W2090340029 @default.
- W2019982783 cites W2090682497 @default.
- W2019982783 cites W2090962881 @default.
- W2019982783 cites W2096928109 @default.
- W2019982783 cites W2097524602 @default.
- W2019982783 cites W2098131572 @default.
- W2019982783 cites W2098685167 @default.
- W2019982783 cites W2101908524 @default.
- W2019982783 cites W2106582859 @default.
- W2019982783 cites W2107966379 @default.
- W2019982783 cites W2110414248 @default.
- W2019982783 cites W2119488344 @default.
- W2019982783 cites W2121939433 @default.
- W2019982783 cites W2128423996 @default.
- W2019982783 cites W2136299255 @default.
- W2019982783 cites W2150065588 @default.
- W2019982783 cites W2157560174 @default.
- W2019982783 cites W2157677292 @default.
- W2019982783 cites W2160457163 @default.
- W2019982783 cites W2164651100 @default.
- W2019982783 cites W2167803257 @default.
- W2019982783 cites W2181120820 @default.
- W2019982783 cites W2313063363 @default.
- W2019982783 cites W2784537797 @default.
- W2019982783 cites W4236042930 @default.
- W2019982783 cites W4239047758 @default.
- W2019982783 cites W4247135558 @default.
- W2019982783 cites W4376849759 @default.
- W2019982783 cites W4211118618 @default.
- W2019982783 doi "https://doi.org/10.1517/13543776.2012.698264" @default.
- W2019982783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22697257" @default.
- W2019982783 hasPublicationYear "2012" @default.
- W2019982783 type Work @default.
- W2019982783 sameAs 2019982783 @default.
- W2019982783 citedByCount "189" @default.
- W2019982783 countsByYear W20199827832012 @default.
- W2019982783 countsByYear W20199827832013 @default.
- W2019982783 countsByYear W20199827832014 @default.
- W2019982783 countsByYear W20199827832015 @default.
- W2019982783 countsByYear W20199827832016 @default.
- W2019982783 countsByYear W20199827832017 @default.
- W2019982783 countsByYear W20199827832018 @default.
- W2019982783 countsByYear W20199827832019 @default.
- W2019982783 countsByYear W20199827832020 @default.
- W2019982783 countsByYear W20199827832021 @default.